Correction to: Journal of Human Hypertension (2005) 19, 569–576. doi: 10.1038/sj.jhh.1001857 Published online 31 March 2005
Since the publication of the above-mentioned article, the authors have identified an error in the first paragraph of the Methods and materials section.
The revised paragraph is given here:
The cost-effectiveness analysis was carried out using a Markov model constructed in the decision-analytic program package DATA (TreeAge Software Inc.). The model predicted costs and quality-adjusted life years (QALYs) over the remaining lifetime of the patients (limited to 110 years of age). The average follow-up time in SCOPE was 3.7 years. Patients in the candesartan group were therefore assumed to be treated with candesartan for a maximum of 4 years. Treatment cost, risk of nonfatal stroke, mortality during the first 4 years, cost of nonfatal stroke and utility reduction from nonfatal stroke were based on data collected in SCOPE. Epidemiological data were used to estimate mortality after the follow-up of the study. The analysis focused exclusively on the effects of candesartan-based antihypertensive treatment on the prevention of nonfatal stroke since there were no significant differences in other cardiovascular events.20
Additional information
The online version of the original article can be found at 10.1038/sj.jhh.1001857
Rights and permissions
About this article
Cite this article
Lundkvist, J., Ekman, M., Kartman, B. et al. Erratum: The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly. J Hum Hypertens 19, 662 (2005). https://doi.org/10.1038/sj.jhh.1001914
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001914